Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells
- PMID: 3983371
Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells
Abstract
[14C]Bromomisonidazole was prepared by direct bromination of [ring-2] [14C]misonidazole in dioxane. The uptake and binding of the two labeled sensitizers were compared in vitro in 1-mm EMT-6 spheroids which contain a necrotic core. Using liquid scintillation counting it was shown that spheroids incubated with 50 microM [14C]bromomisonidazole concentrated drug above levels in the medium by 1 1/2 hr and achieved maximum concentration by 10 hr with no further increase at 23 hr. Spheroids incubated with 50 microM [14C]misonidazole may concentrate the sensitizer more slowly but ultimately reached the same fivefold increase over levels in the medium by 23 hr as was observed for bromomisonidazole. Autoradiographs prepared from spheroids after incubation with [14C]misonidazole or [14C]bromomisonidazole showed silver grains preferentially located over viable hypoxic cells in the inner half of the spheroid rim adjacent to the necrotic center, with lower grain density over nonviable necrotic areas and many fewer grains over oxic cells at the periphery of the spheroid. The results indicate that both severely and moderately hypoxic cells may preferentially bind [14C]bromomisondiazole. The data support the potential of radiolabeled bromomisonidazole for in vivo imaging pending additional studies of the metabolism of this agent.
Similar articles
-
Comparison of binding of [3H]misonidazole and [14C]misonidazole in multicell spheroids.Radiat Res. 1985 Mar;101(3):473-9. Radiat Res. 1985. PMID: 3983363
-
Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.Radiat Res. 1987 Aug;111(2):292-304. Radiat Res. 1987. PMID: 3628717
-
Cytotoxicity of hypoxic cell sensitizers in multicell spheroids.Cancer Clin Trials. 1980 Spring;3(1):73-83. Cancer Clin Trials. 1980. PMID: 7389039
-
Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution.Cancer Res. 1992 Jul 15;52(14):3831-7. Cancer Res. 1992. PMID: 1617656
-
Misonidazole and other hypoxia markers: metabolism and applications.Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1195-202. doi: 10.1016/0360-3016(86)90257-9. Int J Radiat Oncol Biol Phys. 1986. PMID: 3528089 Review.
Cited by
-
Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours.Br J Cancer. 1987 Oct;56(4):395-400. doi: 10.1038/bjc.1987.213. Br J Cancer. 1987. PMID: 3689657 Free PMC article.
-
Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.Br J Cancer. 1995 Dec;72(6):1462-8. doi: 10.1038/bjc.1995.530. Br J Cancer. 1995. PMID: 8519660 Free PMC article.
-
18F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy.Cancers (Basel). 2021 Jul 9;13(14):3449. doi: 10.3390/cancers13143449. Cancers (Basel). 2021. PMID: 34298663 Free PMC article.
-
Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection.Br J Cancer. 1991 Jan;63(1):119-25. doi: 10.1038/bjc.1991.24. Br J Cancer. 1991. PMID: 1989649 Free PMC article.
-
HL-91-technetium-99m: a new marker of viability in ischemic myocardium.J Nucl Cardiol. 1999 May-Jun;6(3):306-15. doi: 10.1016/s1071-3581(99)90043-0. J Nucl Cardiol. 1999. PMID: 10385186